(WASHINGTON, DC) – Israel’s BrainStorm Cell Therapeutics said a mid-stage clinical trial of its adult stem cell treatment showed a “statistically significant” effect in patients with amyotrophic lateral sclerosis (ALS).
According to the ALS Association, 5,600 people in the United States are diagnosed each year with the neurodegenerative disease, also known as Lou Gehrig’s Disease, which has severely disabled British physicist Stephen Hawking.
New data presented at the American Academy of Neurology annual meeting in Washington, DC on April 18  showed that six months after a single administration of the stem cell treatment called NurOwn there was a statistically significant improvement in the rate of decline in Forced Vital Capacity, which measures the amount of air a person can dispense from the lungs.
There was also improvement in the rate of decline in the ALS Functional Rating Score, which tests 12 different functions.
In addition, patients who received NurOwn through an intramuscular injection showed an improvement in the rate of decline in muscle mass in the right arm, the site of NurOwn administration, as compared to the left arm.